These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29783441)

  • 41. Enabling personalized medicine through the use of healthcare information technology.
    Cantor MN
    Per Med; 2009 Sep; 6(5):589-594. PubMed ID: 29783305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
    Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
    Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An ethical and legal overview of pharmacogenomics: perspectives and issues.
    Sillon G; Joly Y; Feldman S; Avard D
    Med Law; 2008 Dec; 27(4):843-57. PubMed ID: 19202860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.
    Walk EE
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):226-34. PubMed ID: 20205056
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare.
    Simmons LA; Dinan MA; Robinson TJ; Snyderman R
    Per Med; 2012 Jan; 9(1):85-91. PubMed ID: 29783292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Personalized medicine--genomic phase].
    Brdicka R
    Cas Lek Cesk; 2009; 148(10):477-80. PubMed ID: 20662409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenomics: the genomics of drug response.
    March R
    Yeast; 2000 Apr; 17(1):16-21. PubMed ID: 10797598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safe and effective medicines for all: is personalized medicine the answer?
    Cascorbi I
    Expert Rev Clin Pharmacol; 2010 Sep; 3(5):627-37. PubMed ID: 22111745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach.
    Zhang A; Sun H; Wang P; Han Y; Wang X
    Complement Ther Med; 2012; 20(1-2):93-9. PubMed ID: 22305254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada.
    Shemie G; Nguyen MT; Wallenburg J; Ratjen F; Knoppers BM
    J Pers Med; 2021 May; 11(5):. PubMed ID: 34067090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Knowledge and attitudes concerning pharmacogenomics among healthcare professionals.
    Dodson C
    Per Med; 2011 Jul; 8(4):421-428. PubMed ID: 29783331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Healthcare payers: a gate or translational bridge to personalized medicine?
    Canestaro WJ; Martell LA; Wassman ER; Schatzberg R
    Per Med; 2012 Jan; 9(1):73-84. PubMed ID: 29783295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin.
    McWilliam A; Lutter R; Nardinelli C
    Per Med; 2008 May; 5(3):279-284. PubMed ID: 29783488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Genomics and personalized medicine].
    Mooser V
    Praxis (Bern 1994); 2014 May; 103(10):567-71. PubMed ID: 24800768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The theory of reference values: an unfinished symphony.
    Siest G; Henny J; Gräsbeck R; Wilding P; Petitclerc C; Queraltó JM; Hyltoft Petersen P
    Clin Chem Lab Med; 2013 Jan; 51(1):47-64. PubMed ID: 23183761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Personalized medicine policy challenges: measuring clinical utility at point of care.
    van Rooij T; Wilson DM; Marsh S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug safety assurance through clinical genotyping: near-term considerations for a system-wide implementation of personalized medicine.
    Kane MD; Springer JA; Sprague JE
    Per Med; 2008 Jul; 5(4):387-397. PubMed ID: 29783464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A case for pharmacogenomics in management of cardiac arrhythmias.
    Kandoi G; Nanda A; Scaria V; Sivasubbu S
    Indian Pacing Electrophysiol J; 2012 Mar; 12(2):54-64. PubMed ID: 22557843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conference Scene: The healthcare reform act, comparative effectiveness research and personalized medicine.
    Ofili E; Sproles D
    Per Med; 2011 Mar; 8(2):133-135. PubMed ID: 29783400
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.